Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 12/20 | 0.59 |
| ▸ | TCF4 | P15884 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GUSB | P08236 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343733 | 1.00 | AURKA (0.59) | AURKATCF4CTNNB1KIF11MAPT | |
| SCHEMBL13836671 | 0.87 | TCF4 (0.64) | AURKATCF4CTNNB1KIF11MAPT | |
| SCHEMBL19994448 | 0.83 | ALDH1A1 (0.59) | MAPTKDM4ENPC1GUSBRAB9A | |
| SCHEMBL13974405 | 0.82 | TCF4 (0.70) | AURKATCF4CTNNB1KIF11MAPT | |
| SCHEMBL31005274 | 0.80 | TCF4 (0.59) | AURKATCF4CTNNB1KIF11MAPT | |
| SCHEMBL17370980 | 0.80 | TCF4 (0.59) | AURKATCF4CTNNB1KIF11MAPT | |
| SCHEMBL31005272 | 0.80 | TCF4 (0.59) | AURKATCF4CTNNB1KIF11MAPT | |
| SCHEMBL2554510 | 0.80 | NPC1 (0.58) | AURKAMAPTKDM4ENPC1GUSB | |
| SCHEMBL1663529 | 0.79 | TCF4 (0.58) | AURKATCF4CTNNB1KIF11MAPT | |
| SCHEMBL29506637 | 0.79 | TCF4 (0.79) | AURKATCF4CTNNB1KIF11MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2025-12-30 | — | — | US | disclosed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| CN-110234640-B | Benzimidazole derivatives as anticancer agents | 利昂贝拉尔中心 | 2023-04-07 | — | — | CN | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| EP-3515904-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | Centre Leon Berard (FR) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018054989-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018054989-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CCAR2, MAPKAP1, BCOR | AURKA 1394/4885TCF4 3369/4885CTNNB1 1287/4885 |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | TMBIM6, BAX, MAPK14 | AURKA 347/4885TCF4 2690/4885CTNNB1 1908/4885 |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | TMBIM6, BAX, MAPK14 | AURKA 347/4885TCF4 2690/4885CTNNB1 1908/4885 |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | TMBIM6, BAX, BCL2 | AURKA 376/4885TCF4 2717/4885CTNNB1 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.